Clin Case Rep . New-onset atypical fulminant type 1 diabetes after COVID-19 vaccination: A case report

[tetano]

Clin Case Rep


. 2022 Oct 17;10(10):e6473.
doi: 10.1002/ccr3.6473. eCollection 2022 Oct.
New-onset atypical fulminant type 1 diabetes after COVID-19 vaccination: A case report


Takaaki Kobayashi[SUP] 1 [/SUP], Fumiyoshi Yakou[SUP] 1 [/SUP], Masuo Saburi[SUP] 1 [/SUP], Ai Hirose[SUP] 1 [/SUP], Hiroaki Akaoka[SUP] 1 [/SUP], Yusuke Hirota[SUP] 1 [/SUP], Daisuke Yunaiyama[SUP] 2 [/SUP], Nobuteru Asahi[SUP] 1 [/SUP], Atsushi Ohno[SUP] 1 [/SUP], Takaya Matsushita[SUP] 1 [/SUP]



Affiliations

• PMID: 36267825
• PMCID: PMC9576963
• DOI: 10.1002/ccr3.6473

Abstract

Adverse reactions, including the onset of diabetes, after coronavirus disease 2019 (COVID-19) vaccination have been reported. Herein, we report a case of a man who developed anti-glutamic acid decarboxylase (GAD) antibody-positive fulminant type 1 diabetes 15 weeks after COVID-19 vaccination, atypical of the previously reported anti-GAD antibody-negative cases.

Keywords: COVID‐19 vaccination; anti‐glutamic acid decarboxylase (GAD) antibody; diabetic ketoacidosis; fulminant type 1 diabetes.